F 0759
Ensure medication error rates are not 5 percent or greater.
Level of Harm - Minimal harm
or potential for actual harm
Based on medical record review, observations, staff interviews, and policy review, the facility failed to
ensure resident's medications were administered as ordered resulting in three medication errors out of 29
opportunities or a 10.3 percent (%) medication error rate. This affected one (#37) out of the two residents
observed for medication administration. The facility census was 37.
Residents Affected - Few
Findings include:
Review of the medical record for Resident #37 revealed an admission date of 01/02/25 with medical
diagnoses of left femur fracture, arthritis, hyperlipidemia, cerebrovascular disease, and dysphagia.
Review of the medical record for Resident #37 revealed an admission Minimum Data Set (MDS)
assessment, dated 01/08/25, which indicated Resident #37 had moderate cognitive impairment and was
dependent for toilet hygiene, bathing, bed mobility, and transfers.
Review of the medical record for Resident #37 revealed physician orders dated 01/03/25 for tamsulosin
(Flomax) 0.4 milligram (mg) one tablet by mouth daily, aspirin-dipyridamole (Aggrenox- an antiplatelet) 12
hour 25-100 mg one tablet by mouth two times per day, and Colace 100 mg one tablet by mouth daily.
Review of the physician orders revealed no documentation to support an order for aspirin 81 mg one tablet
daily.
Review of the medical record for Resident #37 revealed an April 2025 Medication Administration Record
(MAR) which indicated staff administered Colace, tamsulosin, and aspirin-dipyridamole as ordered from
04/01/25 through 04/07/25.
Review of the medical record for Resident #37 revealed a pharmacy recommendation, dated 03/28/25,
which recommended discontinuation of Colace and tamsulosin. The pharmacy recommendation revealed
documentation to support the physician agreed with the pharmacy recommendation and an order to
discontinue the medications was signed on 03/31/25.
Observation on 04/08/25 at 8:05 A.M. revealed Registered Nurse (RN) #114 prepared Resident #37's
medications for administration. The observation revealed RN #114 prepared one Colace 100 mg tablet, one
aspirin 81 mg tablet, and one tamsulosin 0.4 mg tablet for administration. The observation revealed RN
#114 administered the Colace, aspirin, and tamsulosin tablets to Resident #37.
Interview on 04/08/25 at 8:26 A.M. with RN #114 confirmed she administered aspirin 81 mg tablet to
Resident #37 and not the aspirin-dipyridamole 25-100 mg tablet as ordered by physician. RN #114 also
confirmed she also administered Colace and tamsulosin to Resident #37.
(continued on next page)
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other
safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the
date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date
these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE
TITLE
(X6) DATE
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Facility ID:
If continuation sheet
Page 1 of 3
Event ID:
366263
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
366263
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
04/09/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Grace Brethren Village
1010 Taywood Road
Englewood, OH 45322
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0759
Level of Harm - Minimal harm
or potential for actual harm
Interview on 04/09/25 at 1:00 P.M. with Chief Clinical Officer (CCO) #112 confirmed Resident #37's
pharmacy recommendation dated 03/28/25 indicated a recommendation to discontinue Colace and
tamsulosin medications. The pharmacy recommendation revealed documentation the physician
discontinued the orders for Colace and tamsulosin on 03/31/25. Interview with CCO #112 confirmed the
medications were not discontinued and staff administered medications from 04/01/25 through 04/08/25.
Residents Affected - Few
Review of the facility policy titled, Administering Oral Medications, revised October 2010 stated staff are to
verify there is a physician's medication order, check label of the medication, and confirmed the medication
name and dose with Medication Administration Record (MAR), check medication dose, and re-check to
confirm proper dose.
The deficiency was based on incidental findings discovered during the course of this complaint
investigation.
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
366263
If continuation sheet
Page 2 of 3
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
366263
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
04/09/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Grace Brethren Village
1010 Taywood Road
Englewood, OH 45322
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0760
Ensure that residents are free from significant medication errors.
Level of Harm - Minimal harm
or potential for actual harm
Based on medical record reviews, observations, staff interviews, review of medication information from
Medscape, and policy review, the facility failed to ensure residents were free from significant medication
errors. This affected one (#37) out of two residents reviewed for medication administration. The facility
census was 37.
Residents Affected - Few
Findings include:
Review of the medical record for Resident #37 revealed an admission date of 01/02/25 with medical
diagnoses of left femur fracture, arthritis, hyperlipidemia, cerebrovascular disease, and dysphagia.
Review of the medical record for Resident #37 revealed an admission Minimum Data Set (MDS)
assessment, dated 01/08/25, which indicated Resident #37 had moderate cognitive impairment and was
dependent for toilet hygiene, bathing, bed mobility, and transfers.
Review of the medical record for Resident #37 revealed a physician order dated 01/03/25
aspirin-dipyridamole (Aggrenox- an antiplatelet medication) 12 hour 25-100 milligram (mg) one tablet by
mouth two times per day. Review of the physician orders revealed no documentation to support an order for
aspirin 81 mg one tablet daily.
Observation on 04/08/25 at 8:05 A.M. revealed Registered Nurse (RN) #114 prepared Resident #37's
medications for administration. The observation revealed RN #114 prepared one aspirin 81 mg for
administration and administered the aspirin tablet to Resident #37.
Interview on 04/08/25 at 8:26 A.M. with RN #114 confirmed she administered aspirin 81 mg tablet to
Resident #37 and not the aspirin-dipyridamole 25-100 mg tablet as ordered by physician.
Review of the facility policy titled, Administering Oral Medications, revised October 2010 stated staff are to
verify there is a physician's medication order, check label of the medication, and confirmed the medication
name and dose with Medication Administration Record (MAR), check medication dose, and re-check to
confirm proper dose.
Review of medication information from Medscape at
https://reference.medscape.com/drug/aggrenox-aspirin-dipyridamole-342148?_gl=1*19qd2zd*_gcl_au*MTEwNzM0NDc3O
revealed aspirin/dipyridamole is a antiplatelet medication used to treat stroke secondary prophylaxis of
transient ischemic attack (TIA) or cerebrovascular accident (CVA).
The deficiency was based on incidental findings discovered during the course of this complaint
investigation.
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
366263
If continuation sheet
Page 3 of 3